Urticaria

Dr.S A Surale-Patil
Assistant Professor. Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110,Maharashtra

Dr.P.S Salve
Assistant Professor Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110,Maharashtra

Dr. Bhati Bhambu
Tutor.,Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University",Karad –415110,Maharashtra

Abstract
Hives, often referred to as urticaria, are a common dermatological disorder marked by the abrupt emergence of itchy, raised wheals on the skin. With varied causes and underlying pathophysiological mechanisms, it might present as acute or chronic symptoms. This review article offers a thorough summary of the pathogenesis, diagnoses, and available urticaria treatments. The complement system, mast cell activation, and autoimmune components all play a role in the underlying mechanisms of urticaria. Urticaria is accurately identified by diagnostic criteria and clinical signs, and its subgroups are characterized by categorization systems. The management plans for urticaria include non-pharmacological methods like avoiding triggers and stress management techniques as well as pharmaceutical therapies like immunomodulatory drugs and antihistamines. Healthcare providers can improve patient outcomes and raise their quality of life by comprehending the intricacy of urticaria and using the best management techniques.

Keywords: urticaria, hives, wheals, pruritus, pathophysiology, diagnosis, treatment

Introduction

Hives, often referred to as urticaria, are a common dermatological disorder marked by the abrupt emergence of itchy, raised wheals on the skin. As much as 20% of the population may experience it at some point in their lives, and it can affect people of all ages. Patients' quality of life may be significantly impacted by urticaria since it can be uncomfortable, interfere with sleep, and cause mental anguish [1].

Urticaria has a complicated etiology that is influenced by complex interactions between immunological, inflammatory, and environmental variables. Infections, drugs, physical conditions (such as pressure or temperature), food allergies, and autoimmune processes are

just a few of the stimuli that might cause it. Mast cell activation and the consequent production of histamine, prostaglandins, and other inflammatory mediators are the main underlying causes of urticaria [2,3].

For effective care of urticaria, a precise diagnosis is required. The temporary nature of wheals and pruritus, which may spread to various parts of the body, characterizes the clinical presentation of urticaria. Urticaria episodes can be classified as acute (lasting less than six weeks) or chronic (lasting more than six weeks) based on how long they last. Urticaria can be distinguished from other dermatological illnesses using diagnostic criteria, such as a thorough medical history, physical examination, and the discovery of potential triggers. The classification of urticaria subtypes based on clinical characteristics, duration, and underlying etiology is standardized by classification systems, such as the revised guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), Global Allergy and Asthma European Network (GA2LEN), European Dermatology Forum (EDF), and World Allergy Organization (WAO) [4,5].

A multifaceted strategy is used to manage urticaria, including pharmaceutical therapies, trigger detection and avoidance, and patient education. Antihistamines are the cornerstone of treatment for both acute and chronic urticaria, especially second-generation non-sedating antihistamines. Additional treatments, such as omalizumab (an anti-IgE monoclonal antibody), systemic corticosteroids, and immunomodulatory drugs, may be evaluated in patients of chronic urticaria that do not respond to antihistamines [3-6].

The goal of this review paper is to give a thorough understanding of the pathophysiology, diagnostic standards, and available urticaria treatments. Healthcare practitioners can maximize patient care, enhance treatment results, and lessen the burden of urticaria on affected persons by comprehending the underlying mechanisms and applying suitable management measures.

Pathophysiology of Urticaria

Complex interactions between immunological, inflammatory, and environmental variables play a role in the pathophysiology of urticaria. Mast cell activation is crucial for the emergence of urticaria because it triggers the production of many mediators, including as histamine, prostaglandins, and leukotrienes, which are responsible for the urticaria-specific wheal and itch [1]. Wheals develop as a result of vasodilation and increased vascular permeability brought on in particular by histamine [2]. The complement system, which consists of the conventional and alternative routes, is also crucial to understanding the pathophysiology of urticaria. Anaphylatoxins like C3a and C5a are produced when complement is activated, and they can cause mast cells to degranulate and release inflammatory mediators [3].

Autoimmune pathways have been linked to the etiology of chronic urticaria. In a small number of individuals, autoantibodies against the high-affinity IgE receptor (FcRI) or IgE itself have been found, activating mast cells and releasing inflammatory mediators [4]. Autoimmune urticaria usually resists conventional antihistamine medication and is frequently accompanied by a longer illness course.

Additionally, diverse environmental stimuli might cause urticaria episodes through a variety of ways. Acute urticaria has been associated with illnesses, such as viral or bacterial infections [5]. Physical urticaria, which is characterized by the appearance of wheals at the site of stimulation, can be brought on by physical stimuli such as pressure, heat, cold, and vibration [6]. Drug-induced urticaria is frequently triggered by medications, particularly non-steroidal anti-inflammatory medicines (NSAIDs) and antibiotics [7]. Additionally, dietary allergens like shellfish, peanuts, and eggs can cause urticaria episodes, especially in people who already have underlying food allergies [8].

It is essential to comprehend the pathophysiological underpinnings of urticaria in order to create focused therapy strategies and improve patient care.

Diagnostic Criteria and Clinical Manifestations

An extensive analysis of the clinical symptoms and consideration of many variables are required for an accurate diagnosis of urticaria. The diagnosis is mostly based on wheals and pruritus, which have a migratory and distinctive look [7]. The wheals often appear as distinct, elevated, erythematous lesions that range in size and shape. The quality of life of patients is greatly impacted by the urticaria-related pruritus, which can range in intensity from mild to severe [8].

For the diagnosis of urticaria, a detailed medical history and physical examination are just as important as the clinical presentation. A thorough description of the onset, length, and frequency of episodes should be included in the medical history, as well as any possible triggers like drugs, illnesses, or allergen exposure [9]. The goal of the physical examination is to find any wheals and evaluate their distribution and characteristics.

In some circumstances, laboratory examinations are used to aid in the diagnosis and find underlying causes. Skin prick testing can be used to pinpoint the allergens that cause urticaria episodes [10]. In situations of allergic urticaria, measurement of particular IgE antibodies can also offer useful information. Additionally, laboratory biomarkers can be utilized to check for systemic inflammation or underlying illnesses, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC) [11].

Several established categorization systems have been created in order to standardize the classification of urticaria subtypes and facilitate clinical management. The updated EAACI/GA2LEN/EDF/WAO recommendations offer consistent criteria for categorizing urticaria according to its duration, causes, and accompanying conditions [12]. These classification systems help medical personnel identify the exact subtype of urticaria precisely, which can inform prognosis and therapy choices.

Healthcare providers may offer patients focused management methods that are suitable and effective when urticaria is correctly diagnosed and classified, which improves patient outcomes and quality of life.

Management Strategies for Urticaria

The treatment of urticaria involves a multifaceted strategy designed to reduce symptoms, stop recurrences, and enhance patients' quality of life. Pharmacological therapies and non-pharmacological measures can be classified as therapeutic strategies.

In the treatment of urticaria, pharmaceutical interventions are crucial. Antihistamines are regarded as the first-line therapy and work by inhibiting histamine receptors to effectively manage symptoms [13]. Due to their excellent safety profile and efficacy, second-generation non-sedating antihistamines such cetirizine, loratadine, and fexofenadine are recommended [14]. Antihistamine dosage can be increased or combined in situations where regular doses are ineffective [15].

Alternative therapies could be required for patients with persistent urticaria that is resistant to standard therapies. A monoclonal antibody that targets IgE, omalizumab, has demonstrated exceptional effectiveness in easing symptoms and enhancing quality of life in individuals with chronic spontaneous urticaria [16]. For patients who do not respond to antihistamines, it is advised as a second-line treatment [17]. Due to their potential negative effects, systemic corticosteroids are only used in severe situations or for a brief period of time [18]. In some instances of chronic urticaria that is resistant to other treatments, immunomodulatory drugs such cyclosporine or methotrexate may be investigated [19].

Non-pharmacological interventions seek to recognize and keep away from causes that aggravate urticaria symptoms. Patients should be informed about possible triggers and urged to keep a journal in order to recognize and get rid of particular stressors from their surroundings [20]. Modifying one's lifestyle to prevent exposure to harsh temperatures and physical stressors, get enough sleep, and practice stress reduction strategies can also help manage urticaria symptoms [21].

An personalized strategy that takes into account the clinical appearance, severity, and treatment response of the patient is necessary for the best therapy of urticaria. To evaluate the effectiveness of the treatment, modify pharmaceutical dosages as necessary, and keep an eye out for any potential side effects, regular follow-up visits are crucial.

Future Directions and Conclusion

Despite substantial advancements in our knowledge of the pathogenesis, diagnosis, and treatment of urticaria, there are still a number of questions that need to be answered.

Finding biomarkers that can help with urticaria diagnosis, prognosis, and treatment response is one area of active research. The creation of trustworthy biomarkers may be able to distinguish between various urticaria subtypes, gauge the severity of the condition, and direct treatment choices. Numerous biomarkers have been investigated, such as certain IgE antibodies, inflammatory cytokines, and complement components, but more validation and standardization are needed [22].

The investigation of fresh therapeutic targets is an additional research direction. Recent research has concentrated on the part that particular immune cells, like basophils, eosinophils, and T cells, play in the pathogenesis of urticaria. For patients with refractory urticaria,

targeting these cells and the signaling pathways that they are connected to may offer novel therapy options [23].

Further research is necessary to better understand how comorbidities and psychosocial variables affect urticaria. There have been reports of links between urticaria and illnesses such autoimmune diseases, thyroid issues, and psychological stress. Treatment results and overall patient care can be enhanced by comprehending the underlying mechanisms and creating individualized management strategies for patients with urticaria and comorbidities [24].

The widespread dermatological ailment urticaria has a complex origin, a major negative impact on patients' quality of life, and is frequent. For patient care to be optimized, accurate diagnosis, categorization, and management strategies are crucial. Future studies should concentrate on the discovery of trustworthy biomarkers, the investigation of fresh therapeutic targets, and the evaluation of the influence of comorbidities on urticaria. We can improve the management and results for people with urticaria by deepening our understanding of the underlying mechanisms and enhancing treatment options.

Conclusion

Finally, it should be noted that urticaria is a complicated and diverse disorder defined by the emergence of momentary wheals and pruritus. Numerous elements, including as immunological, inflammatory, and environmental stimuli, have an impact on it. The pathophysiology of urticaria is influenced by autoimmune processes, complement system activation, and mast cell activation. For effective therapy techniques, urticaria must be accurately diagnosed and classified.

A rigorous clinical evaluation, including the identification of distinctive wheals and pruritus, a thorough medical history, and a physical examination are all necessary for the diagnosis of urticaria. In some circumstances, laboratory examinations such as skin prick tests and the measurement of particular IgE antibodies might help in determining the triggers and underlying reasons. Validated categorization systems aid in classifying various urticaria subtypes, simplifying prognosis and therapy choices.

Pharmacological and non-pharmacological therapies are used in combination to treat urticaria. The first-line treatment for symptom control is antihistamines, especially second-generation non-sedating antihistamines. In refractory situations, other therapies such omalizumab and immunomodulatory drugs are taken into consideration. Non-pharmacological interventions emphasize lifestyle changes and the identification and avoidance of triggers.

The identification of biomarkers to assist in diagnosis and treatment response prediction, the investigation of novel therapeutic targets, and the comprehension of the influence of comorbidities and psychosocial factors are some future research directions in urticaria. Improvements in these fields may result in more accurate diagnosis, individualized treatment plans, and better outcomes for urticaria patients.

Having a thorough understanding of the pathogenesis, diagnosis, and treatment options is essential for enhancing patient care, reducing symptoms, and raising the quality of life for

urticaria sufferers. Our understanding of and ability to better manage this widespread dermatological illness depends on ongoing study and collaboration among healthcare providers.

Reference

1. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777-787.
2. Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas JF. Pathophysiology of urticaria. *Clin Rev Allergy Immunol*. 2006;30(1):3-11. doi:10.1385/CRIAI:30:1:003.
3. Engelke C, Wiese AV, Schmudde I, et al. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma. *J Immunol*. 2014;193(11):5387-5401. doi:10.4049/jimmunol.1400080.
4. Van Beek J, Bernaudin M, Petit E, et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. *Exp Neurol*. 2000;161(1):373-382. doi:10.1006/exnr.1999.7273
5. Van Beek J, Bernaudin M, Petit E, et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. *Exp Neurol*. 2000;161(1):373-382. doi:10.1006/exnr.1999.7273.
6. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. *Allergy Asthma Clin Immunol*. 2009;5(1):10. Published 2009 Dec 1. doi:10.1186/1710-1492-5-10
7. Kolkhir P, Borzova E, Grattan C, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-178
8. Greaves M. Chronic urticaria in a child: clinical presentation, laboratory investigations and pathogenesis. Pediatr Allergy Immunol. 2000;11(Suppl 13):31-34.
9. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.
10. Godse K, De A, Zawar V, et al. Guidelines for management of urticaria: a dermatology expert group consensus. Indian J Dermatol. 2018;63(2):167-174.
11. dos Santos RV, Magerl M, Mlynek A, Lima HC. Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines. *Ann Allergy Asthma Immunol*. 2009;102(6):495-499. doi:10.1016/S1081-1206(10)60123-8.
12. Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus – a systematic review. Clin Exp Allergy. 2016;46(2):275-287.
13. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
14. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466.
15. Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5(11):125-147.

16. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
17. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869-873
18. Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications. *J Asthma Allergy*. 2019;12:285-295. Published 2019 Sep 20. doi:10.2147/JAA.S184986.
19. Maurer M, Bindslev-Jensen C, Giménez-Arnau A, et al. Chronic idiopathic urticaria (CIU) / chronic spontaneous urticaria (CSU): treatment challenges and special considerations. World Allergy Organ J. 2019;12(10):100066.
20. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307-1313.
21. Gyimesi E, Sipka S, Dankó K, et al. Basophil CD63 expression assay on highly sensitized atopic donor leucocytes-a useful method in chronic autoimmune urticaria. *Br J Dermatol*. 2004;151(2):388-396. doi:10.1111/j.1365-2133.2004.06042.x
22. Philpott H, Kette F, Hissaria P, Gillis D, Smith W. Chronic urticaria: the autoimmune paradigm. *Intern Med J*. 2008;38(11):852-857. doi:10.1111/j.1445-5994.2008.01673.x
23. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. *Allergy*. 2017;72(10):1440-1460. doi:10.1111/all.13182
24. O'Donnell BF, Francis DM, Swana GT, Seed PT, Kobza Black A, Greaves MW. Thyroid autoimmunity in chronic urticaria. *Br J Dermatol*. 2005;153(2):331-335. doi:10.1111/j.1365-2133.2005.06646.x